Physician profile
Yingjun Li
NPI 1154540516
$5,645.69
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,979 · 2020: $1,639 · 2021: $1,949 · 2022: $65.34 · 2023: $12.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $761.33 | 2019-2021 | |
| Allergan, INC. | $717.02 | 2019-2021 | |
| Biogen, INC. | $520.41 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $402.83 | 2019-2021 | |
| Ucb, INC. | $312.33 | 2019-2021 | |
| Abbvie INC. | $244.23 | 2021-2023 | |
| Lilly USA, LLC | $241.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $218.76 | 2020-2021 | |
| Eisai INC. | $202.35 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $187.70 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $165.71 | 2019-2021 | |
| Genzyme Corporation | $155.42 | 2019-2022 | |
| Emd Serono, INC. | $142.87 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $129.18 | 2021 | |
| Amgen INC. | $114.46 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yingjun Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.